Tchem ABL2 Tyrosine-protein kinase ABL2

Protein Summary

Description

Non-receptor tyrosine-protein kinase that plays an ABL1-overlapping role in key processes linked to cell growth and survival such as cytoskeleton remodeling in response to extracellular stimuli, cell motility and adhesion and receptor endocytosis. Coordinates actin remodeling through tyrosine phosphorylation of proteins controlling cytoskeleton dynamics like MYH10 (involved in movement); CTTN (involved in signaling); or TUBA1 and TUBB (microtubule subunits). Binds directly F-actin and regulates actin cytoskeletal structure through its F-actin-bundling activity. Involved in the regulation of cell adhesion and motility through phosphorylation of key regulators of these processes such as CRK, CRKL, DOK1 or ARHGAP35. Adhesion-dependent phosphorylation of ARHGAP35 promotes its association with RASA1, resulting in recruitment of ARHGAP35 to the cell periphery where it inhibits RHO. Phosphorylates multiple receptor tyrosine kinases like PDGFRB and other substrates which are involved in endocytosis regulation such as RIN1. In brain, may regulate neurotransmission by phosphorylating proteins at the synapse. ABL2 acts also as a regulator of multiple pathological signaling cascades during infection. Pathogens can highjack ABL2 kinase signaling to reorganize the host actin cytoskeleton for multiple purposes, like facilitating intracellular movement and host cell exit. Finally, functions as its own regulator through autocatalytic activity as well as through phosphorylation of its inhibitor, ABI1. This gene encodes a member of the Abelson family of nonreceptor tyrosine protein kinases. The protein is highly similar to the c-abl oncogene 1 protein, including the tyrosine kinase, SH2 and SH3 domains, and it plays a role in cytoskeletal rearrangements through its C-terminal F-actin- and microtubule-binding sequences. This gene is expressed in both normal and tumor cells, and is involved in translocation with the ets variant 6 gene in leukemia. Multiple alternatively spliced transcript variants encoding different protein isoforms have been found for this gene. [provided by RefSeq, Nov 2009]

Uniprot Accession IDs

• P42684
• A0M8X0
• B7UEF2
• B7UEF3
• B7UEF4
• B7UEF5
• Q5T0X6
• Q5W0C5
• Q6NZY6
• Q7Z301

Gene Name

• ABL2

Ensembl ID

• ENST00000344730
• ENSP00000339209
• ENSG00000143322
• ENST00000367623
• ENSP00000356595
• ENST00000392043
• ENSP00000375897
• ENST00000502732
• ENSP00000427562
• ENST00000504405
• ENSP00000426831
• ENST00000507173
• ENSP00000423413
• ENST00000511413
• ENSP00000424697
• ENST00000512653
• ENSP00000423578

Symbol

• ABLL
• ARG
• ARG
• ABLL

Knowledge Table

Most Knowledge About	Knowledge Value (0 to 1 scale)
biological process	1
drug perturbation	0.99
molecular function	0.99
protein domain	0.99
kinase perturbation	0.97

Protein Classes

DTO Classes

Protein / Kinase / Protein Kinase / Tk Group / Abl Family / Abelson Tyrosine-protein Kinase 2

IDG Development Level Summary

Tdark

These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 109.33   (req: < 5)

Gene RIFs: 39   (req: <= 3)

Antibodies: 446   (req: <= 50)

Tbio

These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 109.33   (req: >= 5)

Gene RIFs: 39   (req: > 3)

Antibodies: 446   (req: > 50)

- OR - satisfy the following criterion:

Gene Ontology Terms: 26

Tchem

Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions

Active Ligands: 21

Tclin

Target has at least one approved drug - AND - satisfies the preceding conditions

Active Drugs: 5